Vivoryon Therapeutics N.V. Revenue and Competitors

Halle (Saale),

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Vivoryon Therapeutics N.V.'s estimated annual revenue is currently $5M per year.(i)
  • Vivoryon Therapeutics N.V.'s estimated revenue per employee is $201,000

Employee Data

  • Vivoryon Therapeutics N.V. has 25 Employees.(i)
  • Vivoryon Therapeutics N.V. grew their employee count by 4% last year.

Vivoryon Therapeutics N.V.'s People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Vivoryon Therapeutics N.V.?

Vivoryon Therapeutics has an experienced discovery and development team with a strong track record in delivering therapies to patients. We have product-candidates in both clinical and preclinical development and are focusing on age-related diseases with unmet medical need. We are relentless and focused on putting patients at the center of everything we do and strive to develop life-changing medicines.

keywords:N/A

N/A

Total Funding

25

Number of Employees

$5M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vivoryon Therapeutics N.V. News

2022-04-17 - Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022

Halle (Saale) / Munich, Germany, April 21, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical...

2022-04-17 - Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to ...

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Conference Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at...

2022-04-13 - While shareholders of Vivoryon Therapeutics (AMS:VVY) are in the black over 3 years, those who bought a week ago aren't so fortunate

The last three months have been tough on Vivoryon Therapeutics N.V. (AMS:VVY) shareholders, who have seen the share price decline a rather...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.9M327%N/A
#2
$10.8M41-2%N/A
#3
$11.1M7952%N/A
#4
$20.7M1155%N/A